scholarly journals Dydrogesterone in the treatment of the threatened and habitual miscarriage

2018 ◽  
pp. 68-72 ◽  
Author(s):  
N. K. Tetruashvili ◽  
A. A. Agadzhanova

The article presents the findings of the studies evaluating the efficacy of gestagens in the treatment of the threatened and habitual miscarriage. It summarizes a number of meta-analysis related to the comparative evaluation of the use of various gestagens during pregnancy. The foreign societies’ guidelines for the treatment of reproductive disorders and the management of early pregnancy in women with the threatened and habitual miscarriage are outlined.

2016 ◽  
Vol 89 (5) ◽  
pp. 739-753 ◽  
Author(s):  
Dohyung Kim ◽  
Mo-Yeol Kang ◽  
Sungyeul Choi ◽  
Jaechan Park ◽  
Hye-Ji Lee ◽  
...  

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
E V Woon ◽  
O Greer ◽  
N Shah ◽  
V Male ◽  
M Johnson

Abstract Study question Do women with recurrent miscarriage (RM) or implantation failure (RIF) have different levels of uterine Natural Killer (NK) cells compared to fertile controls? Summary answer Women with RIF but not RM are associated with significantly higher levels of CD56+ uterine NK cells compared to controls. What is known already Uterine NK cells (uNK) are different from peripheral NK cells (pNK) and are important in early pregnancy for development of the placenta. The association between uNK and RM/RIF is less clear, but dysfunction of uNK is believed to result in early pregnancy failure. Previous systematic reviews by Seshadri (2014) and Tang (2013) on infertile and RM patients showed no significant difference in uNK levels and highlighted need for further studies. Since, many prospective studies have been published and therefore warrant an updated systematic review. On the other hand, evidence for correlation between uNK and pNK is sparse and needs clarification. Study design, size, duration We have conducted a systematic review and meta-analysis to evaluate three outcomes. The primary outcome was the difference of uNK level in RM/RIF compared to controls. The secondary outcome was livebirth rate in women with RM/RIF with high compared to normal uNK level, and the tertiary outcome was correlation between uNK and pNK in RM/RIF. Participants/materials, setting, methods The electronic database search included MEDLINE, EMBASE, Web of Science and bibliographies from included articles from inception to December 2020 using a combination of MESH and keywords. Search, screen, and data extraction were performed by two reviewers independently. Quality assessment was conducted with ROBINS-I and meta-analysis with Revman 5.3. Out of 4636 studies screened, 43 studies (2539 women) and 3 studies each (598 and 77 women) were analysed for primary, secondary and tertiary outcomes respectively. Main results and the role of chance Our meta-analysis showed that CD56+ uNK were significantly higher in women with RIF but not RM compared to controls (SMD 0.60; 95% CI 0.12–1.08]. Subgroup analysis in RM patients showed no significant difference whether definition of 2 or 3 previous RM was used, in primary/secondary RM compared to controls, or in primary versus secondary RM. CD56+ uNK were significantly higher in RM/RIF when sampled during mid-luteal phase [SMD 0.56; 95% CI 0.19–0.93] but not in the early pregnancy decidua. Interestingly, there was significant difference in CD56+ uNK when analysed by immunohistochemistry [SMD 0.50; CI 0.05–0.94] but not by flow cytometry, and when CD56+ uNK were reported as percentage over total endometrial cells [SMD 0.58; 95% CI 0.10–1.07]. Further subgroup analysis showed significant difference in CD16 + [SMD 0.54; 95% CI 0.18–0.89] but not in CD56+CD16-, CD56+CD16+ or CD57. For pregnancy outcome, there was no significant difference in livebirth rate in RM/RIF patients with high uNK compared to normal uNK [RR 1.06, 95% CI 0.86–1.30]. Mean uNK level in RM patients with subsequent miscarriage was not significantly higher than subsequent livebirth. Finally, the pooled correlation between CD56 pNK and CD56 uNK (r = 0.42; 95% CI –0.04–0.73] was not significant in RM/RIF patients. Limitations, reasons for caution The meta-analysis is limited by quality of some of the studies. Some data were presented in median that was transformed to mean which may result in data skew. Other confounding factors e.g. maternal age, fetal karyotype, number of previous miscarriages and variable definition of controls may contribute to bias. Wider implications of the findings: Clinical interpretation of uNK level needs to be treated with caution because there is significant heterogeneity in method of analysis. There may be a role for uNK measurement in RIF patients however further studies to understand pathophysiology underlying elevated uNK is warranted before recommending it as a diagnostic tool. Trial registration number N/A


BMJ ◽  
2012 ◽  
Vol 345 (sep27 4) ◽  
pp. e6077-e6077 ◽  
Author(s):  
J. Verhaegen ◽  
I. D. Gallos ◽  
N. M. van Mello ◽  
M. Abdel-Aziz ◽  
Y. Takwoingi ◽  
...  

2014 ◽  
Vol 20 (4) ◽  
pp. 582-593 ◽  
Author(s):  
C. Tersigni ◽  
R. Castellani ◽  
C. de Waure ◽  
A. Fattorossi ◽  
M. De Spirito ◽  
...  

2016 ◽  
Vol 17 (S5) ◽  
Author(s):  
Vincenzo Lagani ◽  
Argyro D. Karozou ◽  
David Gomez-Cabrero ◽  
Gilad Silberberg ◽  
Ioannis Tsamardinos

2021 ◽  
pp. 39-44
Author(s):  
Paul Piette

The etiopathology of recurrent miscarriage is a combination of various factors, including chromosomal defects, genetic or structural abnormalities, endocrine abnormalities, infections, immune dysfunction, thrombophilia disorders, antiphospholipid syndrome, and unexplained causes.It has long been known that progesterone is needed to maintain pregnancy and its physiological development. Insufficient progesterone secretion and its low level in the blood serum in early pregnancy is associated with the threat of miscarriage and loss of pregnancy at a later stage – up to 16 weeks of gestation. The effectiveness of the vaginal micronized progesterone (VMP) at a dose of 400 mg twice a day in the first trimester of pregnancy was evaluated in two recent large high-quality multicenter placebo-controlled studies, one of which included pregnant women with recurrent miscarriages of unexplained origin (PROMISE Trial), and the other study included women with early pregnancy loss (PRISM Trial). A key finding, pioneered in the PROMISE study and later confirmed in the PRISM study, was that VMP treatment associated with an increase in live births in line with the number of previous miscarriages. It has been shown that there is no evidence regarding safety concerns with natural micronized progesterone. Treatment with an VMP should be recommended for women with bleeding in early pregnancy and a history of one or more miscarriages. The recommended treatment regimen is 400 mg 2 times a day (800 mg/day) intravaginal, starting from the moment bleeding is detected up to 16 weeks of pregnancy.In the future, there remains uncertainty effectiveness and safety of alternative progestogens (dydrogesterone) for the treatment of women at high risk of threatened abortion and recurrent miscarriage. It is important that dydrogesterone is a synthetic progestin, its structure is significantly different from natural progesterone, and therefore it is necessary to unequivocally prove the short- and long-term safety of this drug before considering its use in clinical practice.


Author(s):  
Hesti Yuniastutiningsih ◽  
Dini Nafi'ati

Physical and psychological changes experienced by pregnant women, especially hormonal changes, cause symptoms of nausea and vomiting in early pregnancy. Excessive nausea and vomiting in early pregnancy and persist throughout pregnancy will cause physical and psychological complications. The existence of psychological problems in pregnant women can predispose to nausea and vomiting which then worsens. Emotional problems are also associated with the incidence of nausea and vomiting becoming more severe. Methods: the authors conducted extensive searches by scientific journals through trusted and frequently used databases, namely PubMed, Springer, and Science Direct. The keywords used were "hyperemesis" AND "psychological" with journal publication filters, the last 4 years, randomized clinical trials, systematic reviews, meta-analysis, human research subjects. Conclusion: care that focuses on mothers by applying the principles of holistic care, where patients not only receive midwifery care physically and biologically but include psychological, social, spiritual and cultural by involving their husbands in midwifery care is proven to accelerate the physical and psychological recovery of hyperemesis sufferers.


Sign in / Sign up

Export Citation Format

Share Document